These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 8204938

  • 21. Treatment of metastatic uveal melanoma with intravenous fotemustine.
    Spagnolo F, Grosso M, Picasso V, Tornari E, Pesce M, Queirolo P.
    Melanoma Res; 2013 Jun; 23(3):196-8. PubMed ID: 23624366
    [Abstract] [Full Text] [Related]

  • 22. Uveal melanomas. Conservation treatment.
    Munzenrider JE.
    Hematol Oncol Clin North Am; 2001 Apr; 15(2):389-402. PubMed ID: 11370500
    [Abstract] [Full Text] [Related]

  • 23. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
    Daponte A, Ascierto PA, Gravina A, Melucci MT, Palmieri G, Comella P, Cellerino R, DeLena M, Marini G, Comella G, Italian Cooperative Oncology Group.
    Cancer; 2000 Dec 15; 89(12):2630-6. PubMed ID: 11135225
    [Abstract] [Full Text] [Related]

  • 24. Treatment of primary intraocular cancers: retinoblastoma and uveal malignant melanoma.
    Boyd-Monk H, Augsburger JJ.
    J Ophthalmic Nurs Technol; 1997 Dec 15; 16(4):183-7. PubMed ID: 9335732
    [No Abstract] [Full Text] [Related]

  • 25. [Trends and developments in the management of malignant uveal melanoma].
    Lund OE.
    Klin Oczna; 1988 Dec 15; 90(4-5):159-64. PubMed ID: 3071651
    [No Abstract] [Full Text] [Related]

  • 26. Response of patients with metastatic uveal melanoma to combined treatment with fotemustine and sorafenib.
    Niederkorn A, Wackernagel W, Artl M, Schwantzer G, Aigner B, Richtig E.
    Acta Ophthalmol; 2014 Dec 15; 92(8):e696-7. PubMed ID: 24774993
    [No Abstract] [Full Text] [Related]

  • 27. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
    Bosch JJ, Thompson JA, Srivastava MK, Iheagwara UK, Murray TG, Lotem M, Ksander BR, Ostrand-Rosenberg S.
    Cancer Res; 2007 May 01; 67(9):4499-506. PubMed ID: 17483366
    [Abstract] [Full Text] [Related]

  • 28. Long-term follow-up after uveal melanoma charged particle therapy.
    Char DH, Kroll SM, Castro J.
    Trans Am Ophthalmol Soc; 1997 May 01; 95():171-87; discussion 187-91. PubMed ID: 9440169
    [Abstract] [Full Text] [Related]

  • 29. [Immunochemotherapy of metastatic uveal melanoma with interferon alfa-2b, interleukin-2 and fotemustine. Case reports and review of the literature].
    Terheyden P, Kämpgen E, Rünger TM, Bröcker EB, Becker JC.
    Hautarzt; 1998 Oct 01; 49(10):770-3. PubMed ID: 9857252
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Treatment of intraocular melanoma: new concepts].
    De Potter P.
    Bull Mem Acad R Med Belg; 2003 Oct 01; 158(1-2):103-11; discussion 111-2. PubMed ID: 12852096
    [Abstract] [Full Text] [Related]

  • 32. Treatment considerations for primary uveal melanoma with choroidal metastasis to the fellow eye.
    Bourla DH, Young TA.
    Semin Ophthalmol; 2007 Oct 01; 22(3):175-7. PubMed ID: 17763240
    [Abstract] [Full Text] [Related]

  • 33. Apoptosis inhibitor, survivin, in posterior uveal melanoma: comparison among primary tumors, tumors resistant to brachytherapy, tumors with liver metastases, and liver metastases.
    Ben Simon GJ, Abulafia A, Pe'er J.
    Curr Eye Res; 2006 Mar 01; 31(3):251-7. PubMed ID: 16531282
    [Abstract] [Full Text] [Related]

  • 34. [Adjuvant chemotherapy of intraocular malignant melanoma. Apropos of 20 cases].
    Sellami M, Weil M, Maral J, Auclerc G, Dhermy P, Aron-Rosa D, Jacquillat C.
    J Fr Ophtalmol; 1985 Mar 01; 8(5):423-6. PubMed ID: 3937848
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Effect of radiation dose on ocular complications after iodine brachytherapy for large uveal melanoma: empirical data and simulation of collimating plaques.
    Puusaari I, Heikkonen J, Kivelä T.
    Invest Ophthalmol Vis Sci; 2004 Oct 01; 45(10):3425-34. PubMed ID: 15452045
    [Abstract] [Full Text] [Related]

  • 37. Current treatments and trials in uveal melanoma.
    Char DH.
    Oncology (Williston Park); 1989 Sep 01; 3(9):113-21; discussion 122, 124, 127-8. PubMed ID: 2701697
    [Abstract] [Full Text] [Related]

  • 38. [Uveal melanomas and their treatment].
    Zografos L.
    Rev Med Suisse Romande; 1998 Nov 01; 118(11):915-26. PubMed ID: 9865119
    [No Abstract] [Full Text] [Related]

  • 39. Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy.
    Salmon RJ, Levy C, Plancher C, Dorval T, Desjardins L, Leyvraz S, Pouillart P, Schlienger P, Servois V, Asselain B.
    Eur J Surg Oncol; 1998 Apr 01; 24(2):127-30. PubMed ID: 9591028
    [Abstract] [Full Text] [Related]

  • 40. [Bilateral uveal melanomas. Five case reports].
    Bhouri L, Lumbroso L, Levy C, Dendale R, Asselain B, Plancher C, Sastre X, Desjardins L.
    J Fr Ophtalmol; 2003 Feb 01; 26(2):149-53. PubMed ID: 12660588
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.